The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Related Articles
Maj (Dr.) Riordan Ledgerwood
Major (Dr.) Riordan Ledgerwood has dedicated their life to healing others. Riordan’s groundbreaking career spans nearly a decade of service, from excelling as a resident…
Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel: A CIBMTR Study
Key Points. Compared to younger and non-frail patients, older adults and frail patients treated with ide-cel experience comparable efficacy.Higher rates of
Artificial Intelligence in Cancer Care and Clinical Trials
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.
Bill Gates calls Elon Musk’s embrace of far-right politicians abroad ‘insane shit’
Microsoft co-founder and philanthropist calls fellow tech titan ‘super-smart’ but guilty of ‘overreach’
Opinion | The World’s Richest Men Take On the World’s Poorest Children
I’ve seen U.S.A.I.D. operate around the world, and it’s not woke — it’s lifesaving.
Fourth Annual National General Medical Oncology Summit | Research To Practice
Friday-Sunday, February 28 – March 2, 2025, Miami, Florida Dates Friday to Sunday February 28 to March 2, 2025 Location Fontainebleau Miami Beach 4441 Collins…
Silencing science: How Trump is reshaping US health
Medical researchers left to compile national data by hand, contraceptive guidelines deemed essential by doctors erased, and the nation’s largest tuberculosis outbreak left unreported: President…
Former President Trump faces criticism for using language reminiscent of Hitler
Former President Donald Trump recently referred to his political opponents as vermin. That language echoes language used by Adolf Hitler, and raises questions about authoritarianism…
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | NEJM
Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to…
